REVIEW ON CHRONIC MYELOID LEUKEMIA

B pharmacy

In the past decade clinical and laboratory studies have led to important new insights into the biology of chronic myeloid leukemia (CML). Basic science has defined the molecular pathogenesis of CML as unregulated signal transduction by a tyrosine kinase. Clinical science has demonstrated that it is curable through immune-mediated elimination of leukemia cells by allogeneic T lymphocytes. Clinical Features CML is a malignant clonal disorder of hematopoietic stem cells that results in increases in not only myeloid cells but also erythroid cells and platelets in peripheral blood and marked myeloid hyperplasia in the bone marrow.[1] Chronic myeloid leukemia (CML) is probably the most extensively studied human malignancy. CML was first described in 1844/5 when Virchow coined the term leukemia (Leukämie). This is the commonest myeloproliferative neoplasm and possibly the commonest adult leukemia. chronic myeloid leukemia is also known as Chronic myelogenous leukemia. It is charachterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. Consequently, the peripheral blood cell profile shows an increased number of granulocytes and their immature precursors, including occasional blast cells. CML accounts for 20% of all leukemias affecting adults.[1]

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.